




FY2008 3Q Business Results

February 3, 2009

IR & Corporate Communication Div.

Sysmex Corporation

Results for the First 9 Months of FY2008



Exchange rate in the preceding First 9 Months: 1US\$=¥117.3, 1EUR=¥162.8
 Exchange rate in this First 9 Months: 1US\$=¥102.8, 1EUR=¥150.7

Exchange rate in the preceding 3Q report: 1US\$=¥ 113.2, 1EUR=¥163.9
 Exchange rate in this 3Q report: 1US\$=¥ 96.3, 1EUR=¥126.7

(In billions of JPY)	First 9 Months of FY2008	First 9 Months of FY2007	% over a Year Earlier
Net sales	80.6	78.3	102.9%
Operating income	10.0	9.8	102.9%
Ordinary income	7.8	10.4	75.4%
Net income	4.6	6.6	69.8%

- **Sales and Operating income increased**
 - ✓ Forex impact Net sales: - ¥5.80 billion
Operating income: - ¥0.84 billion
 - ※Currency adjusted to the same time last year
Net sales: + 10.3%, Operating income: + 11.4%
 - **Ordinary income and Net income decreased**
 - ✓ Non-operating balance: - ¥2.2 billion
(incl. Forex loss of ¥2.4 billion)
 - ✓ Extraordinary profits/losses: - ¥0.55 billion
Loss on disposal of Fixed assets: - ¥0.35 billion
Devaluation of Inventories: - ¥0.34 billion
- ※R&D Expenditure: ¥7.5 billion, Depreciation: ¥5.5 billion,
Capital Expenditure: ¥7.9 billion

Changes in Accounting Standards



Accounting Standards for Lease

- Direct leasing contracts
 - ✓ Sales in Europe: - ¥0.9 billion
 - ✓ Small impact on Operation income, Ordinary income and Net income
- Leased assets/liabilities now on-balance
 - ✓ Tangible fixed assets: + ¥3.8 billion

Valuation of Inventory

- Inventory now valued using the weighted average method (essentially lower of cost or market method)
 - ✓ COGS: + ¥0.14 billion
 - ✓ Extraordinary loss: ¥0.34 billion

Reclassification of Service Costs in the Americas

- Service costs reclassified from COGS to SG&A expenses
 - ✓ SG&A expenses: + ¥2.2 billion

New Products

- Breast cancer lymph node metastasis rapid detection system: First insurance coverage in Japan
- POCTEM Avian Influenza (Japan's first rapid influenza diagnostic kit for chickens)

Affiliates and Offices

- R&D center Technopark opened in Kobe
- A subsidiary in the Middle East (Dubai) began operations in November 2008
- An Indian joint venture was made a wholly-owned subsidiary

Other Developments

- Sysmex corporate logo changed
- Sales and support for Quantachrome's powder measurement devices began in January 2009

Japan - Geographic Segment Information -

<Including Korea, Taiwan, and Mongolia>



(In billions of JPY)	First 9 Months of FY2008	First 9 Months of FY2007	% over a Year Earlier
Net sales	50.2	45.9	109.3%
Sales to customers	25.5	24.7	103.4%
Intra-area Transfer	24.6	21.1	116.2%
Operating income	4.0	5.3	75.4%


- The Japanese market remained slow
- Large orders received in the hematology field
- Regaining share in the hemostasis market
- Brisk exports (inter-group sales)
- Operating margin fell due to increase in COGS from the appreciation of the yen

※Temporary factors resulted in greater SG&A expenses

40th anniversary events: ¥0.35 billion

Establishment of Technopark (excluding depreciation): ¥0.43 billion

※Combined sales of Korea, Taiwan, and Mongolia: ¥1.36 billion




Americas - Geographic Segment Information -



(In billions of JPY)	First 9 Months of FY2008	First 9 Months of FY2007	% over a Year Earlier
Net sales	17.3	15.0	115.6%
Operating income	1.1	0.66	168.8%

*On a local currency basis: Net sales; +32.0%, Operating income; +92.3%

- Sales in the hematology field grew substantially in the US
- Switchover to direct sales on schedule in Canada
- Instrument sales increased sharply (more quickly than reagent sales)
- Operating margin improved due to increased sales in direct sales territories




Europe - Geographic Segment Information -



(In billions of JPY)	First 9 Months of FY2008	First 9 Months of FY2007	% over a Year Earlier
Net sales	26.7	29.0	92.2%
Operating income	3.7	34.1	110.2%

*On a local currency basis: Net sales; -0.4%, Operating income; +19.0%



- Changes from the previous fiscal year which have affected our sales (special factors)
 - Change in accounting standards for lease transactions: -¥0.90 billion
 - MOLIS software transferred: -¥0.67 billion
 - Distributed product lines discontinued (blood-collecting tubes): -¥0.40 billion
- Reagents sales grew in France and emerging markets (Eastern Europe, Russia, etc.)
- Operating margin improved due to reagents sales growth and change in distribution channels (France, the Middle East) etc.


China - Geographic Segment Information -



(In billions of JPY)	First 9 Months of FY2008	First 9 Months of FY2007	% over a Year Earlier
Net sales	6.8	6.0	113.7%
Operating income	0.83	0.62	133.5%

*On a local currency basis: Net sales; +18.0%, Operating income; +38.2%

- Hematology systems sales increased through direct business with customers
- Successful bid ratio decreased in the hematology low-end market, following a new law on the control of purchasing/imports (Feb. 2008)
- Reagents sales grew substantially in the hematology (high-end models), urinalysis, and coagulation fields
- Urinalysis analyzer sales grew strongly due to upgrading and in the wake of reports of melamine-contaminated food



AP - Geographic Segment Information -




<Excluding Korea, Taiwan, and Mongolia>

(In billions of JPY)	First 9 Months of FY2008	First 9 Months of FY2007	% over a Year Earlier
Net sales	4.0	3.5	115.6%
Operating income	0.51	0.45	112.6%

*On a local currency basis: Net sales; +24.2%, Operating income; +20.9%

- Hematology systems sales fared well in Australia
- Sales in the hematology low-end market grew substantially in India
- Urinalysis sales increased as the use of automated urine sediment analysis has become widespread
- Sales and support structure in India realigned



Consolidated Earnings Forecast

<Revised in February 3, 2009>



FY2008 Consolidated Earnings Forecast


- Net sales: ¥114 billion
- Operating Income: ¥14.0 billion
- Ordinary Income: ¥11.5 billion
- Net Income : ¥6.7 billion

Investment plan

- Capital Expenditure: ¥12.0 billion
- R&D Expenditure: ¥11.0 billion

Planned exchange rate : US\$1= ¥95, EUR1= ¥120(4Q)

※Exchange rate (announced on May):
US\$1= ¥100, EUR1= ¥157





We Believe the Possibilities.

Forward-looking Statements

This material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysmex Group). These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations, and changes in operating environment both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements, or financial position either expressed or implied within these forward-looking statements.

Sysmex Corporation

<Contact>

IR & Corporate Communication Div.

Phone: +81-78-265-0500

Email: info@sysmex.co.jp

URL www.sysmex.co.jp